M P Cohen

Summary

Publications

  1. ncbi Normalizing glycated albumin reduces increased urinary collagen IV and prevents renal insufficiency in diabetic db/db mice
    Margo P Cohen
    Institute of Metabolic Research and Exocell, University City Science Center, Philadelphia, PA, USA
    Metabolism 51:901-5. 2002
  2. ncbi Intervention strategies to prevent pathogenetic effects of glycated albumin
    Margo P Cohen
    Institute for Metabolic Research, University City Science Center, 3508 Market Street, Suite 420, Philadelphia, PA 19104, USA
    Arch Biochem Biophys 419:25-30. 2003
  3. doi Clinical, pathophysiological and structure/function consequences of modification of albumin by Amadori-glucose adducts
    Margo P Cohen
    Glycadia, Inc, 1880 JFK Boulevard, Suite 200, Philadelphia, PA 19103, United States Electronic address
    Biochim Biophys Acta 1830:5480-5. 2013
  4. ncbi Increased plasma glycated low-density lipoprotein concentrations in diabetes: a marker of atherogenic risk
    Margo P Cohen
    Institute for Metabolic Research, University City Science Center, Philadelphia, Pennsylvania 19104, USA
    Diabetes Technol Ther 6:348-56. 2004
  5. ncbi Evidence linking glycated albumin to altered glomerular nephrin and VEGF expression, proteinuria, and diabetic nephropathy
    Margo P Cohen
    University City Science Center, Institute of Metalboic Research, Philadelphia, Pennsylania 19104, USA
    Kidney Int 68:1554-61. 2005
  6. pmc Amadori-modified glycated serum proteins and accelerated atherosclerosis in diabetes: pathogenic and therapeutic implications
    Margo P Cohen
    University City Science Center, Philadelphia, Pennsylvania, USA
    J Lab Clin Med 147:211-9. 2006
  7. ncbi Inhibiting albumin glycation attenuates dysregulation of VEGFR-1 and collagen IV subchain production and the development of renal insufficiency
    Margo P Cohen
    University City Science Center, Philadelphia, Pennsylvania, USA
    Am J Physiol Renal Physiol 292:F789-95. 2007
  8. ncbi Vitreous fluid of db/db mice exhibits alterations in angiogenic and metabolic factors consistent with early diabetic retinopathy
    Margo P Cohen
    Glycadia, Inc, Philadelphia, PA, USA
    Ophthalmic Res 40:5-9. 2008
  9. doi Amelioration of diabetes-associated abnormalities in the vitreous fluid by an inhibitor of albumin glycation
    Margo P Cohen
    Glycadia, Inc, Philadelphia, Pennsylvania 19103, USA
    Invest Ophthalmol Vis Sci 49:5089-93. 2008
  10. doi Reduction of Abeta42 in brains of transgenic APPswe mice by 2-3-chlorophenylaminophenylacetate
    Margo P Cohen
    Glycadia Inc, Philadelphia, Pennsylvania 19103, USA
    Clin Exp Pharmacol Physiol 36:1099-103. 2009

Research Grants

Detail Information

Publications24

  1. ncbi Normalizing glycated albumin reduces increased urinary collagen IV and prevents renal insufficiency in diabetic db/db mice
    Margo P Cohen
    Institute of Metabolic Research and Exocell, University City Science Center, Philadelphia, PA, USA
    Metabolism 51:901-5. 2002
    ....
  2. ncbi Intervention strategies to prevent pathogenetic effects of glycated albumin
    Margo P Cohen
    Institute for Metabolic Research, University City Science Center, 3508 Market Street, Suite 420, Philadelphia, PA 19104, USA
    Arch Biochem Biophys 419:25-30. 2003
    ..Potential intervention strategies to lessen the influence of AGE-modified proteins, as well as of other contributory abnormalities, are discussed elsewhere in this volume...
  3. doi Clinical, pathophysiological and structure/function consequences of modification of albumin by Amadori-glucose adducts
    Margo P Cohen
    Glycadia, Inc, 1880 JFK Boulevard, Suite 200, Philadelphia, PA 19103, United States Electronic address
    Biochim Biophys Acta 1830:5480-5. 2013
    ..The nonenzymatic condensation of glucose with albumin results in the formation of albumin modified by Amadori glucose adducts, the principal form in which glycated albumin exists in vivo...
  4. ncbi Increased plasma glycated low-density lipoprotein concentrations in diabetes: a marker of atherogenic risk
    Margo P Cohen
    Institute for Metabolic Research, University City Science Center, Philadelphia, Pennsylvania 19104, USA
    Diabetes Technol Ther 6:348-56. 2004
    ....
  5. ncbi Evidence linking glycated albumin to altered glomerular nephrin and VEGF expression, proteinuria, and diabetic nephropathy
    Margo P Cohen
    University City Science Center, Institute of Metalboic Research, Philadelphia, Pennsylania 19104, USA
    Kidney Int 68:1554-61. 2005
    ....
  6. pmc Amadori-modified glycated serum proteins and accelerated atherosclerosis in diabetes: pathogenic and therapeutic implications
    Margo P Cohen
    University City Science Center, Philadelphia, Pennsylvania, USA
    J Lab Clin Med 147:211-9. 2006
  7. ncbi Inhibiting albumin glycation attenuates dysregulation of VEGFR-1 and collagen IV subchain production and the development of renal insufficiency
    Margo P Cohen
    University City Science Center, Philadelphia, Pennsylvania, USA
    Am J Physiol Renal Physiol 292:F789-95. 2007
    ..The findings indicate that inhibiting excess nonenzymatic glycation of serum albumin improves renal molecular biology abnormalities and protects against the development of renal insufficiency in the db/db mouse...
  8. ncbi Vitreous fluid of db/db mice exhibits alterations in angiogenic and metabolic factors consistent with early diabetic retinopathy
    Margo P Cohen
    Glycadia, Inc, Philadelphia, PA, USA
    Ophthalmic Res 40:5-9. 2008
    ....
  9. doi Amelioration of diabetes-associated abnormalities in the vitreous fluid by an inhibitor of albumin glycation
    Margo P Cohen
    Glycadia, Inc, Philadelphia, Pennsylvania 19103, USA
    Invest Ophthalmol Vis Sci 49:5089-93. 2008
    ....
  10. doi Reduction of Abeta42 in brains of transgenic APPswe mice by 2-3-chlorophenylaminophenylacetate
    Margo P Cohen
    Glycadia Inc, Philadelphia, Pennsylvania 19103, USA
    Clin Exp Pharmacol Physiol 36:1099-103. 2009
    ..5. These results are the first to demonstrate that GLY-230, which exhibits antiglycation but no cyclo-oxygenase inhibitory properties, lowers brain Abeta42 levels in this experimental model of Alzheimer's disease...
  11. pmc Inhibiting low-density lipoprotein glycation ameliorates increased cholesteryl ester synthesis in macrophages and hypercholesterolemia and aortic lipid peroxidation in streptozotocin diabetic rats
    Margo P Cohen
    Glycadia, Inc, Philadelphia, PA 19103, USA
    Metabolism 59:658-63. 2010
    ..These results are the first to demonstrate that inhibiting nonenzymatic glycation of apo B-containing lipoproteins ameliorates abnormalities contributory to hypercholesterolemia and atherogenic risk in diabetes...
  12. ncbi Glycated albumin increases oxidative stress, activates NF-kappa B and extracellular signal-regulated kinase (ERK), and stimulates ERK-dependent transforming growth factor-beta 1 production in macrophage RAW cells
    Margo P Cohen
    Institute of Metabolic Research, University City Science Center, Research University of Pennsylvania, 3508 Market Street, Suite 420, Philadelphia, PA 19104, USA
    J Lab Clin Med 141:242-9. 2003
    ..The effects of glycated albumin on RAW cell molecular mediators and cytokine production may have pathophysiologic significance with respect to the accelerated atherosclerosis that occurs in diabetes...
  13. ncbi Increased collagen IV excretion in diabetes. A marker of compromised filtration function
    M P Cohen
    IMR, University City Science Center, Philadelphia, Pennsylvania 19104, USA
    Diabetes Care 24:914-8. 2001
    ..We postulated that the overproduction of extracellular matrix proteins underlying glomerulosclerosis in diabetes might be associated with the excretion of increased amounts of type IV collagen in the urine...
  14. ncbi Inhibiting albumin glycation in vivo ameliorates glomerular overexpression of TGF-beta1
    Margo P Cohen
    Institute of Metabolic Research and Exocell, University City Science Center, Philadelphia, PA 19104, USA
    Kidney Int 61:2025-32. 2002
    ..Whether glycated albumin modulates glomerular TGF-beta1 expression in vivo is not known. To address this issue, we assessed glomerular TGF-beta1 expression and pathology in response to reducing the burden of glycated albumin in vivo...
  15. ncbi Inhibiting albumin glycation ameliorates diabetic nephropathy in the db/db mouse
    M P Cohen
    University City Science Center, Philadelphia, PA, USA
    Exp Nephrol 8:135-43. 2000
    ..We conclude that normalization of plasma glycated albumin concentrations with the glycation inhibitor EXO-226 ameliorates the glomerular structural and functional abnormalities associated with diabetic nephropathy in the db/db mouse...
  16. ncbi Measuring glycated proteins: clinical and methodological aspects
    M P Cohen
    Exocell, Inc, and Institute for Metabolic Research, University City Science Center, Philadelphia, Pennsylvania, USA
    Diabetes Technol Ther 1:57-70. 1999
    ..This article reviews the chemistry, methods for measurement, and clinical relevance of circulating glycated proteins in the management of diabetes...
  17. ncbi Serum type IV collagen in diabetic patients at risk for nephropathy
    M P Cohen
    Institute for Metabolic Research, University City Science Center, Philadelphia, Pennsylvania 19104, USA
    Diabetes Care 24:1324-7. 2001
    ..We sought to clarify the relationship between early renal dysfunction in diabetes and circulating type IV collagen concentrations...
  18. ncbi Prevention of decline in renal function in the diabetic db/db mouse
    M P Cohen
    University City Science Center, Philadelphia, Pennsylvania, USA
    Diabetologia 39:270-4. 1996
    ....
  19. ncbi Glycated albumin stimulates TGF-beta 1 production and protein kinase C activity in glomerular endothelial cells
    S Chen
    Renal-Electrolyte and Hypertension Division, University of Pennsylvania, Philadelphia, Pennsylvania 19104-6144, USA
    Kidney Int 59:673-81. 2001
    ....
  20. ncbi ERK mediates effects of glycated albumin in mesangial cells
    M P Cohen
    Institute of Metabolic Research and Exocell, Inc, University City Science Center, Philadelphia, Pennsylvania, 19104, USA
    Biochem Biophys Res Commun 283:641-3. 2001
    ..These findings indicate that the MAPK/ERK pathway mediates biologic activities of this glycated protein...
  21. ncbi Increased urinary type IV collagen marks the development of glomerular pathology in diabetic d/db mice
    M P Cohen
    Institute for Metabolic Research, University City Science, Philadelphia, PA, USA
    Metabolism 50:1435-40. 2001
    ..The findings suggest that increased urinary type IV collagen is a better indicator than albuminuria of developing glomerular matrix accumulation that results in compromised renal filtration function...
  22. ncbi The renal TGF-beta system in the db/db mouse model of diabetic nephropathy
    M P Cohen
    Department of Medicine, University of Pennsylvania, Philadelphia, USA
    Exp Nephrol 6:226-33. 1998
    ....
  23. ncbi Identification of calnexin as a binding protein for Amadori-modified glycated albumin
    V Y Wu
    Institute of Metabolic Research, University City Science Center, Philadelphia, Pennsylvania 19104, USA
    Biochem Biophys Res Commun 284:602-6. 2001
    ..These results indicate that one of the mesangial cell receptors for glycated albumin is a calnexin-like protein...

Research Grants3

  1. Point-of-Care Measurement of Glycated Hemoglobin
    MARGO COHEN; Fiscal Year: 2004
    ....
  2. Reducing Renal TGF-B in Diabetic Glomerulosclerosis
    MARGO COHEN; Fiscal Year: 2005
    ..abstract_text> ..
  3. LDL Modification in Diabetic Complications
    MARGO COHEN; Fiscal Year: 2007
    ..This Phase II SBIR project will advance to the clinical stage a novel compound that prevents modifications of lipoproteins that occur in diabetes and that contribute to the development of these complications. ..